Irinotecan dose schedule for the treatment of Ewing sarcoma

Irinotecan and temozolmide achieve objective responses in patients with Ewing sarcoma that recurs after initial therapy. Optimal dose schedules have not been defined. We reviewed published series of patients treated with irinotecan and temozolomide for Ewing sarcoma that recurred after initial therapy. We compared objective response rates for patients who received 5-day irinotecan treatment schedules to response rates for patients who achieved 10-day irinotecan treatment schedules. Among 89 patients treated with a 10-day irinotecan schedule, there were 47 objective responses (53%). Among 180 patients treated with a 5-day irinotecan schedule, there were 52 responses (29%). In the treatment of recurrent Ewing sarcoma, investigators should consider the use of a 10-day schedule for administration of irinotecan.

Automated summary

This study reviewed the use of irinotecan and temozolomide in patients with recurrent Ewing sarcoma. The results showed that a 10-day irinotecan treatment schedule had a higher objective response rate compared to a 5-day schedule. Therefore, the use of a 10-day irinotecan schedule should be considered in the treatment of recurrent Ewing sarcoma.